Navigation
Metabolic psychiatry targeting metabolic dysregulation in mental health
Systemic metabolic abnormalities such as insulin resistance, lipid dysregulation, mitochondrial dysfunction, and inflammation are prevalent in psychiatric illnesses, contributing to increased mortality, illness severity, and treatment resistance. This review synthesizes evidence of the relationship between metabolic dysfunction and mental health outcomes across various disorders, emphasizing the bidirectional interactions between brain function and metabolic state.
This review explores the impact of psychotropic medications, stressors, and disease mechanisms on metabolic burden, as well as how systemic dysfunction can impair brain structure and function. Emerging metabolism-based interventions in psychiatry are discussed, including pharmacologic agents such as metformin, glucagon-like peptide-1 agonists, and pioglitazone, alongside lifestyle strategies like intermittent fasting, ketogenic therapy, and exercise.
Theoretical models such as mitochondrial dysfunction, the allostatic load model, and the selfish brain hypothesis are also reviewed. This review summarizes the interventions, their outcomes, and provides a ranked assessment of the current evidence and recommendations, indicating that while some metabolic-based approaches show promise, others remain too preliminary for definitive conclusions. This highlights the necessity for further human trials.
In conclusion, this review addresses practical and safety considerations, acknowledges limitations in existing literature, and proposes future directions to create a more integrated model of mental and metabolic health. [NPID: metabolic dysfunction, psychiatric illness, brain function]
Year: 2026
